Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

9
NGEx Resources May Be Rio Tinto Acquisition Target To Bolster Copper Production

2018-07-10 seekingalpha
A news article last week explained that Rio Tinto is actively seeking to acquire a big copper project, as it aims to diversify its metal production.
NSU NDMWF RTPPF RIO RIO RIO NAK RTNTF FQVLF NGQRF FQM NGQ

0
NGEX REPORTS FIRST QUARTER 2018 RESULTS

2018-05-10 globenewswire
Vancouver, May 09, 2018 (GLOBE NEWSWIRE) -- NGEx Resources Inc. (TSX: NGQ) (OMX: NGQ) (“NGEx” or the “Company”) is pleased to announce its results for the three months ended March 31, 2018.
NGQRF NGQ

0
NGEx Provides Update on Exploration Program at Nacimientos Project, Argentina

2018-04-23 globenewswire
NGEx Resources Inc. (TSX: NGQ) (Nasdaq Stockholm: NGQ) (“NGEx” or the “Company”) is pleased to report that it has started a three to four hole scout drilling program at its new Nacimientos copper/gold project located in San Juan Province, Argentina. This first pass program is designed to test some of the ideas and targets generated earlier this season before the onset of the southern hemisphere winter.
NGQRF NGQ

0
NGEx Provides Update on Exploration Program at Nacimientos Project, Argentina

2018-04-23 globenewswire
VANCOUVER, British Columbia, April 23, 2018 (GLOBE NEWSWIRE) -- NGEx Resources Inc. (TSX:NGQ) (Nasdaq Stockholm:NGQ) (“NGEx” or the “Company”) is pleased to report that it has started a three to four hole scout drilling program at its new Nacimientos copper/gold project located in San Juan Province, Argentina. This first pass program is designed to test some of the ideas and targets generated earlier this season before the onset of the southern hemisphere winter.
NGQRF NGQ

0
NGEx Share Capital and Voting Rights Update

2018-03-29 globenewswire
Vancouver, March 29, 2018 (GLOBE NEWSWIRE) -- NGEx Resources Inc. ("NGEx" or the “Company”) (TSX: NGQ; NASDAQ Stockholm: NGQ), reports the following share capital and voting rights update in accordance with the Swedish Financial Instruments Trading Act.
NGQRF NGQ

0
NGEx Share Capital and Voting Rights Update

2018-03-29 globenewswire
VANCOUVER, British Columbia, March 29, 2018 (GLOBE NEWSWIRE) -- NGEx Resources Inc. ("NGEx" or the “Company”) (TSX:NGQ) (NASDAQ Stockholm:NGQ), reports the following share capital and voting rights update in accordance with the Swedish Financial Instruments Trading Act.
NGQRF NGQ

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 65339B100